Prasugrel Versus Placebo in Adult Sickle Cell Disease

Summary

The purpose of this trial is to assess the safety of Prasugrel in adult patients with sickle cell disease (SCD) by monitoring the rate and severity of hemorrhagic events requiring medical intervention compared to placebo for 30 days.

Timeline

Start

2010-07

Primary completion

2011-06

Completion

2011-06

Drugs

Indications